Texxon Holding Ltd
NPT Nasdaq Wholesale-Chemicals & Allied Products Financials FY2023–FY2025
What Texxon Holding Ltd does
No business description yet.
- Legal name
- Texxon Holding Ltd
- Fiscal year ends
- June 30, 2025
- Latest annual report
- 20-F · Nov 18, 2025
- Accession · CIK
- 0001213900-25-111812
0002014337
Revenue and margins
Texxon Holding Ltd had $797M of revenue in fiscal 2025, up 18.5% on the year before.
Net income and earnings per share
Loss periods are shown in red.
Returns on capital
After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Cash flow
Free cash flow was −$42.8M in fiscal 2025, −5.4% of revenue. Cash from operations minus capital spending.
Dividends, buybacks and share count
Texxon Holding Ltd returned — to shareholders in fiscal 2025. The diluted share count rose 0.0%.
Balance sheet
Cash, debt and the ratios that show how comfortably Texxon Holding Ltd can carry it.
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | $1.3M | $0.3M | $2.5M |
| Debt incl. finance leases | — | $51.6M | $73.4M |
| Net debt / EBITDA | — | 51.7x | — |
| Current ratio | — | 0.3x | 0.3x |
| Quick ratio | — | 0.3x | 0.3x |
| Total assets | $74.9M | $89.7M | $139M |
| Total liabilities | — | $57.3M | $105M |
| Shareholders' equity | $33.1M | −$2.8M | −$3.8M |
| Net debt (− = net cash) | — | $51.3M | $70.9M |
Insider trades
Open-market purchases and sales by officers, directors and 10% owners, from Form 4 filings. “Plan” marks trades under a pre-arranged Rule 10b5-1 plan.
Bought, 12 months
$0.0M
0 insiders
Sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
No open-market insider trades in the last 12 months.
Piotroski F-score
Nine pass/fail tests of profitability, funding and efficiency. 8–9 is strong, 0–2 weak.
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | ✓ | ✓ | ✕ |
| Cash from operations is positive | ✕ | ✕ | ✓ |
| Return on assets rose | — | ✕ | ✕ |
| Cash from operations exceeds net income | ✕ | ✕ | ✓ |
| Debt fell relative to assets | — | — | ✓ |
| Current ratio rose | — | — | ✕ |
| Share count didn't rise | — | ✓ | ✓ |
| Gross margin rose | — | ✓ | ✕ |
| Revenue rose relative to assets | — | ✓ | ✕ |
| F-score | — / 3 | 4 / 7 | 4 / 9 |
| Accruals ratio | 21.6% | 38.6% | −2.8% |
| Altman Z'' | — | −3.00 | −2.62 |
3 years of figures
Amounts in USD. Hover a ratio’s name for its definition.
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | $553M | $673M | $797M |
| Gross profit | $3.5M | $4.8M | $4.7M |
| Operating income | $1.3M | $0.7M | −$0.6M |
| Pretax income | $2.1M | $3.2M | −$0.7M |
| Income tax | $0.0M | $0.7M | $0.7M |
| Net income | $2.0M | $1.0M | −$0.9M |
| Diluted EPS | $0.10 | $0.05 | −$0.05 |
| Diluted shares | 0.02B | 0.02B | 0.02B |
| Cash flow | |||
| Cash from operations | −$14.2M | −$30.8M | $2.3M |
| Capital expenditure | $22.6M | $33.3M | $45.1M |
| Free cash flow | −$36.8M | −$64.1M | −$42.8M |
| Depreciation and amortization | $0.3M | $0.3M | $0.3M |
| Balance sheet | |||
| Cash and short-term investments | $1.3M | $0.3M | $2.5M |
| Total debt | — | $51.6M | $73.4M |
| Current assets | — | $18.0M | $20.8M |
| Current liabilities | — | $57.3M | $72.7M |
| Inventory | — | $0.9M | $1.0M |
| Property and equipment, net | — | $23.4M | $84.6M |
| Intangible assets | — | $6.2M | $6.2M |
| Total assets | $74.9M | $89.7M | $139M |
| Total liabilities | — | $57.3M | $105M |
| Shareholders' equity | $33.1M | −$2.8M | −$3.8M |
| Margins | |||
| Gross margin | 0.6% | 0.7% | 0.6% |
| Operating margin | 0.2% | 0.1% | −0.1% |
| EBITDA margin | 0.3% | 0.1% | −0.0% |
| Net margin | 0.4% | 0.1% | −0.1% |
| FCF margin | −6.7% | −9.5% | −5.4% |
| Returns | |||
| Return on capital | — | 1.1% | −0.7% |
| Return on capital employed | — | 2.0% | −0.9% |
| Return on equity | 6.1% | 6.3% | — |
| Return on assets | 2.7% | 1.2% | −0.8% |
| Return on tangible equity | 6.1% | — | — |
| Growth | |||
| Revenue growth | — | 21.7% | 18.5% |
| Net income growth | — | −52.8% | −197.8% |
| EPS growth | — | −50.0% | −200.0% |
| Share count change | — | 0.0% | 0.0% |
| Financial health | |||
| Net debt / EBITDA | — | 51.7x | — |
| Current ratio | — | 0.3x | 0.3x |
| Quick ratio | — | 0.3x | 0.3x |
| Capital allocation | |||
| Capex / revenue | 4.1% | 5.0% | 5.7% |
| Quality scores | |||
| Piotroski F-score | — | 4.0 | 4.0 |
| Altman Z'' | — | −3.0 | −2.6 |
| Accruals ratio | 21.6% | 38.6% | −2.8% |
Source: SEC EDGAR XBRL filings (CIK 0002014337). Data updated October 24, 2026. Quarterly fourth quarters are the full year minus the first nine months. For information only — not investment advice. Check the original filings before relying on any figure.